You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Details for New Drug Application (NDA): 074726


✉ Email this page to a colleague

« Back to Dashboard


NDA 074726 describes KLOR-CON M20, which is a drug marketed by Upsher Smith Labs and is included in one NDA. It is available from nine suppliers. Additional details are available on the KLOR-CON M20 profile page.

The generic ingredient in KLOR-CON M20 is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
Summary for 074726
Tradename:KLOR-CON M20
Applicant:Upsher Smith Labs
Ingredient:potassium chloride
Patents:0
Pharmacology for NDA: 074726
Mechanism of ActionOsmotic Activity
Physiological EffectIncreased Large Intestinal Motility
Inhibition Large Intestine Fluid/Electrolyte Absorption
Suppliers and Packaging for NDA: 074726
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KLOR-CON M10 potassium chloride TABLET, EXTENDED RELEASE;ORAL 074726 ANDA Upsher-Smith Laboratories, LLC 0245-5317 0245-5317-01 100 BLISTER PACK in 1 CARTON (0245-5317-01) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0245-5317-89)
KLOR-CON M10 potassium chloride TABLET, EXTENDED RELEASE;ORAL 074726 ANDA Upsher-Smith Laboratories, LLC 0245-5317 0245-5317-10 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (0245-5317-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength20MEQ
Approval Date:Nov 20, 1998TE:AB1RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Aug 9, 2000TE:AB1RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength15MEQ
Approval Date:Jun 6, 2003TE:AB1RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links